SENP1 and cancer: Tumors with positive SENP1 immunostaining showed a significantly shortened PSA recurrence-free interval if all cancers were jointly analyzed (p < 0.0001, Fig. 4a), as well as in subsets of ERG-IHC-positive (p < 0.0001, Fig. 4b) or ERG-IHC-negative cancers p < 0.0001, Fig. 4c).